Renvela is a brand name of sevelamer, approved by the FDA in the following formulation(s):
RENVELA (sevelamer carbonate - for suspension; oral)
Manufacturer: GENZYME
Approval date: February 18, 2009
Strength(s): 2.4GM/PACKET [RLD]
Manufacturer: GENZYME
Approval date: August 12, 2009
Strength(s): 800MG/PACKET
RENVELA (sevelamer carbonate - tablet; oral)
Manufacturer: GENZYME
Approval date: October 19, 2007
Strength(s): 800MG [RLD]
Has a generic version of Renvela been approved?
No. There is currently no therapeutically equivalent version of Renvela available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renvela. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Phosphate-binding polymers for oral administration
Patent 5,496,545
Issued: March 5, 1996
Inventor(s): Holmes-Farley; Stephen R. & Mandeville, III; W. Harry & Whitesides; George M.
Assignee(s): GelTex Pharmaceuticals, Inc.
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- August 11, 2013✓✓
- August 11, 2013
Phosphate-binding polymers for oral administration
Patent 5,667,775
Issued: September 16, 1997
Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
Assignee(s): GelTex Pharmaceuticals, Inc.
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- September 16, 2014✓
- September 16, 2014
Method of making phosphate-binding polymers for oral administration
Patent 6,509,013
Issued: January 21, 2003
Inventor(s): Stephen Randall; Holmes-Farley & W. Harry; Mandeville, III & George M.; Whitesides
Assignee(s): GelTex Pharmaceuticals, Inc.
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- August 11, 2013✓
- August 11, 2013
Method of making phosphate-binding polymers for oral administration
Patent 6,858,203
Issued: February 22, 2005
Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
Assignee(s): Genzyme Corporation
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- August 11, 2013✓✓
- August 11, 2013
Phosphate-binding polymers for oral administration
Patent 7,014,846
Issued: March 21, 2006
Inventor(s): Holmes-Farley; Stephen Randall & Manderville, III; W. Harry & Whitesides; George M.
Assignee(s): Genzyme Corporation
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- August 11, 2013✓✓
- August 11, 2013
Phosphate-binding polymers for oral administration
Patent 7,459,151
Issued: December 2, 2008
Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
Assignee(s): Genzyme Corporation
Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Patent expiration dates:
- August 11, 2013✓
- August 11, 2013
Aliphatic amine polymer salts for tableting
Patent 7,985,418
Issued: July 26, 2011
Inventor(s): Bhagat; Hitesh R. & Goldberg; Jeffrey M. & Harianawala; Abizer I. & Brenner; Louis
Assignee(s): Genzyme Corporation
The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.Patent expiration dates:
- October 27, 2025✓
- October 27, 2025
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 19, 2010 - NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
- August 12, 2012 - NEW DOSAGE FORM
See also...
- Renvela Consumer Information (Drugs.com)
- Renvela Consumer Information (Wolters Kluwer)
- Renvela Powder Packets Consumer Information (Wolters Kluwer)
- Renvela Consumer Information (Cerner Multum)
- Renvela Advanced Consumer Information (Micromedex)
- Sevelamer Consumer Information (Wolters Kluwer)
- Sevelamer Powder Packets Consumer Information (Wolters Kluwer)
- Sevelamer Consumer Information (Cerner Multum)
- Sevelamer Advanced Consumer Information (Micromedex)
- Sevelamer AHFS DI Monographs (ASHP)
No comments:
Post a Comment